Clinical Trial Update: Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating the combination of durvalumab and tremelimumab in advanced gastroenteropancreatic and lung-origin neuroendocrine neoplasms; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | Phase 2 | Status: COMPLETED | Results posted: 2025-01-09